 | Up a level |
Shelan, Mohamed; Achard, Vérane; Appiagyei, Felix; Mose, Lucas; Zilli, Thomas; Fankhauser, Christian D; Zamboglou, Constantinos; Mohamad, Osama; Aebersold, Daniel M; Cathomas, Richard (2024). Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials. (In Press). Prostate cancer and prostatic diseases Nature 10.1038/s41391-024-00829-9
Armstrong, Andrew J; Li, Xiaotong; Tucker, Matthew; Li, Shantao; Mu, Xinmeng Jasmine; Eng, Kenneth Wha; Sboner, Andrea; Rubin, Mark; Gerstein, Mark (2021). Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate cancer and prostatic diseases, 24(3), pp. 786-793. Springer Nature 10.1038/s41391-021-00324-5
Tosco, L; Laenen, A; Briganti, A; Gontero, P; Karnes, R J; Albersen, M; Bastian, P J; Chlosta, P; Claessens, F; Chun, F K; Everaerts, W; Gratzke, C; Graefen, M; Kneitz, B; Marchioro, G; Salas, R S; Tombal, B; Van den Broeck, T; Moris, L; Battaglia, A; ... (2017). The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Prostate cancer and prostatic diseases, 20(4), pp. 407-412. Nature 10.1038/pcan.2017.29
Lee, D; Fontugne, J; Gumpeni, N; Park, K; MacDonald, T Y; Robinson, B D; Sboner, A; Rubin, Mark Andrew; Mosquera, J M; Barbieri, C E (2017). Molecular alterations in prostate cancer and association with MRI features. Prostate cancer and prostatic diseases, 20(4), pp. 430-435. Nature 10.1038/pcan.2017.33
Minciacchi, V R; Zijlstra, A; Rubin, Mark Andrew; Di Vizio, D (2017). Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? Prostate cancer and prostatic diseases, 20(3), pp. 251-258. Nature 10.1038/pcan.2017.7
Moltzahn, Felix Roman; Karnes, J; Gontero, P; Kneitz, B; Tombal, B; Bader, P; Briganti, A; Montorsi, F; Van Poppel, H; Joniau, S; Spahn, Martin (2015). Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. Prostate cancer and prostatic diseases, 18(1), pp. 31-37. Nature 10.1038/pcan.2014.41
